Logo image of IRD

OPUS GENETICS INC (IRD) Stock Price, Quote, News and Overview

NASDAQ:IRD - Nasdaq - US67577R1023 - Common Stock - Currency: USD

1.21  +0.01 (+0.83%)

After market: 1.2 -0.01 (-0.83%)

IRD Quote, Performance and Key Statistics

OPUS GENETICS INC

NASDAQ:IRD (7/24/2025, 8:00:02 PM)

After market: 1.2 -0.01 (-0.83%)

1.21

+0.01 (+0.83%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week HighN/A
52 Week LowN/A
Market Cap72.19M
Shares59.66M
Float42.57M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-11 2025-08-11
IPO11-30 2004-11-30


IRD short term performance overview.The bars show the price performance of IRD in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30 40

IRD long term performance overview.The bars show the price performance of IRD in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of IRD is 1.21 USD. In the past month the price increased by 24.72%.

OPUS GENETICS INC / IRD Daily stock chart

IRD Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.58 337.08B
AMGN AMGEN INC 14.86 165.91B
GILD GILEAD SCIENCES INC 14.63 140.81B
VRTX VERTEX PHARMACEUTICALS INC N/A 121.28B
REGN REGENERON PHARMACEUTICALS 12.74 60.96B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 42.77B
ARGX ARGENX SE - ADR 102.91 36.13B
ONC BEONE MEDICINES LTD-ADR 7.56 32.08B
BNTX BIONTECH SE-ADR N/A 27.54B
SMMT SUMMIT THERAPEUTICS INC N/A 20.48B
INSM INSMED INC N/A 19.64B
BIIB BIOGEN INC 8.38 19.43B

About IRD

Company Profile

IRD logo image Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. The company is headquartered in Durham, North Carolina and currently employs 18 full-time employees. The company went IPO on 2004-11-30. The firm is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.

Company Info

OPUS GENETICS INC

8 Davis Drive, Suite 220

Durham NORTH CAROLINA US

Employees: 18

IRD Company Website

IRD Investor Relations

Phone: 12486819815

OPUS GENETICS INC / IRD FAQ

What is the stock price of OPUS GENETICS INC today?

The current stock price of IRD is 1.21 USD. The price increased by 0.83% in the last trading session.


What is the ticker symbol for OPUS GENETICS INC stock?

The exchange symbol of OPUS GENETICS INC is IRD and it is listed on the Nasdaq exchange.


On which exchange is IRD stock listed?

IRD stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for OPUS GENETICS INC stock?

7 analysts have analysed IRD and the average price target is 7.96 USD. This implies a price increase of 557.52% is expected in the next year compared to the current price of 1.21. Check the OPUS GENETICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is OPUS GENETICS INC worth?

OPUS GENETICS INC (IRD) has a market capitalization of 72.19M USD. This makes IRD a Micro Cap stock.


How many employees does OPUS GENETICS INC have?

OPUS GENETICS INC (IRD) currently has 18 employees.


What are the support and resistance levels for OPUS GENETICS INC (IRD) stock?

OPUS GENETICS INC (IRD) has a support level at 1.1 and a resistance level at 1.22. Check the full technical report for a detailed analysis of IRD support and resistance levels.


Is OPUS GENETICS INC (IRD) expected to grow?

The Revenue of OPUS GENETICS INC (IRD) is expected to grow by 81.34% in the next year. Check the estimates tab for more information on the IRD EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy OPUS GENETICS INC (IRD) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does OPUS GENETICS INC (IRD) stock pay dividends?

IRD does not pay a dividend.


When does OPUS GENETICS INC (IRD) report earnings?

OPUS GENETICS INC (IRD) will report earnings on 2025-08-11.


What is the Price/Earnings (PE) ratio of OPUS GENETICS INC (IRD)?

OPUS GENETICS INC (IRD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.05).


What is the Short Interest ratio of OPUS GENETICS INC (IRD) stock?

The outstanding short interest for OPUS GENETICS INC (IRD) is 2.44% of its float. Check the ownership tab for more information on the IRD short interest.


IRD Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to IRD.


Chartmill TA Rating
Chartmill Setup Rating

IRD Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to IRD. The financial health of IRD is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

IRD Financial Highlights

Over the last trailing twelve months IRD reported a non-GAAP Earnings per Share(EPS) of -1.05. The EPS decreased by -114.29% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -121.7%
ROE -245.11%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%17.24%
Sales Q2Q%155.41%
EPS 1Y (TTM)-114.29%
Revenue 1Y (TTM)-28.2%

IRD Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to IRD. The Buy consensus is the average rating of analysts ratings from 7 analysts.

For the next year, analysts expect an EPS growth of 22.26% and a revenue growth 81.34% for IRD


Ownership
Inst Owners17.15%
Ins Owners5.48%
Short Float %2.44%
Short Ratio0.81
Analysts
Analysts80
Price Target7.96 (557.85%)
EPS Next Y22.26%
Revenue Next Year81.34%